Clinical Trials Browser

Phase 2 × Interventional × Biochemically Recurrent Prostate Carcinoma × Clear all

NCT04336943 2025-08-11

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Phase 2 Terminated

6 enrolled 10 charts

Biochemically Recurrent Prostate Carcinoma